BioInvent International AB
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS5
PHASE 3 / 2-30
RECRUITING3
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO60%
Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +38.0 months). See all sponsors →
Open BioInvent International AB on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| pembrolizumab (KEYTRUDA®) NCT06784648 |
P1/2 | Active, not recruiting | Melanoma Metastatic; Melanoma of Skin | 35 | 2026-09-09 (-25 mo) |
| BI-1910 NCT06205706 |
P1/2 | Active, not recruiting | Solid Tumors; Non Small Cell Lung Cancer | 35 | 2027-07-14 |
| BI-1206 NCT03571568 |
P1/2 | Recruiting | Indolent B-Cell Non-Hodgkin Lymphoma | 140 | 2027-09-30 (+87 mo) |
| BI1206 NCT04219254 |
P1/2 | Recruiting | Solid Tumor, Adult | 197 | 2027-11 (+42 mo) |
| BI-1808 NCT04752826 |
P1/2 | Recruiting | Advanced Malignancies; Ovarian Cancer | 250 | 2028-01-31 (+38 mo) |